Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

June 8, 2024

Study Completion Date

June 8, 2024

Conditions
Parkinson DiseaseMovement Disorders
Interventions
DRUG

Altropane (123I) Injection

Each participant received a single intravenous (IV) administration of 5 millicuries (mCi) (185 megabecquerels \[MBq\]) of Altropane (123I) Injection on Day 1. Altropane SPECT images were acquired for 30 minutes starting 15 to 20 minutes after administration with Altropane. These images were visually interpreted by 5 expert independent blinded readers.

Trial Locations (4)

21287

Johns Hopkins University, Baltimore

39216

University of Mississippi Medical Center (UMMC), Jackson

55905

Mayo Clinic, Rochester

68198

University of Nebraska Medical Center, Omaha

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Fortrea

INDUSTRY

lead

GE Healthcare

INDUSTRY

NCT05636852 - Altropane Dose for Imaging Patients With Suspected Parkinson's Disease | Biotech Hunter | Biotech Hunter